Virax Biolabs Group Ltd Dossier
Qualitative Analysis
Business overview
Virax Biolabs Group Ltd (NASDAQ: VRAX) is an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its proprietary ViraxImmune™ platform and its ImmuneSelect portfolio of research-use-only (RUO) products and services, the company is building an advanced immune-profiling offering. Its primary clinical and diagnostic focus is on post-acute infection syndromes (PAIS), including Long COVID, post-treatment Lyme disease (PTLD), and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Virax aims to address these large, under-served diagnostic categories by leveraging T cell-based test technologies to identify immune cell dysfunction and persistent immune exhaustion.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Developing a proprietary T-cell-based technology platform (ViraxImmune™) for profiling immunology and managing post-viral syndromes like Long COVID, ME/CFS, and Post-Treatment Lyme Disease (PTLD). The company's current U.S. market-entry focus is a Laboratory Developed Test (LDT) pathway, with broader in vitro diagnostic (IVD) development intended to follow over time.
Expected impact: Positioning Virax as a pioneer in the Post-Acute Infection Syndromes (PAIS) diagnostic market, addressing an estimated U.S. economic burden in excess of $25 billion.
Expanding the ImmuneSelect research-use-only (RUO) portfolio of immune-profiling reagents, peptide pools, and ELISpot plates.
Expected impact: Serves as a nearer-term commercial revenue bridge that can be commercialized for research use without waiting for diagnostic approvals.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
The Emory Laboratory for Innovative Assay Development (ELIAD) and the Center for the Advancement of Diagnostics for a Just Society (ADJUST Center) conduct patient recruitment, testing, and analysis to generate clinical data supporting U.S. regulatory and potential commercial plans for ViraxImmune™ in post-acute sequelae of COVID-19 (PASC).
Terms: Not disclosed